Security key
47103J105
Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share (JANX)
CUSIP: 47103J105
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 66,482,175
- Total 13F value
- $1,805,570,973
- Share change
- +2,356,283
- Put/Call ratio
- 25%
- SEC-reported price per share
- $27.00
- Number of holders
- 179
- Value change
- -$17,647,630
- Number of buys
- 114
- Number of sells
- 95
- Shares outstanding
- 60,419,303
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
179
Top holders
10
JANX full security history
Ownership snapshot
Full 13F holder table
Janux Therapeutics, Inc. SEC filings
Janux Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of JANX - Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
15/15
Latest evidence
31 Dec 2024
13F
13D/G
Lead comparable stake: 20%
13D/G row: RA CAPITAL MANAGEMENT, L.P.
Showing 1-6 of 15 holder rows.
Quick read
RA CAPITAL MANAGEMENT, L.P. leads the comparable SEC ownership view at 20%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Comparable ownership
Top 5
RA CAPITAL MANAGEMENT, L.P.
20%
FMR LLC
14%
Janus Henderson Group Ltd.
5.9%
Paradigm Biocapital Advisors LP
5.8%
ADAGE CAPITAL PARTNERS GP, L.L.C.
5.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
Company
|
20%
from 13D/G
|
$554,977,008
10,365,652 shares
|
— | 31 Dec 2024 |
| FMR LLC |
13F
Company
|
14%
|
$464,188,623
8,669,941 shares
|
— | 31 Dec 2024 |
| Janus Henderson Group Ltd. |
13F
Company
|
5.9%
|
$190,617,226
3,562,402 shares
|
— | 31 Dec 2024 |
| Paradigm Biocapital Advisors LP |
13F
Company
|
5.8%
|
$188,245,890
3,515,986 shares
|
— | 31 Dec 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
Company
|
5.1%
|
$163,926,095
3,061,750 shares
|
— | 31 Dec 2024 |
| BlackRock, Inc. |
13F
Company
|
4.5%
|
$145,940,039
2,725,813 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
179
Shares
66,482,175
Rows available
179
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2025 Across Filers
Q1 2025 holders
179
Q1 2025 holders
179
Holder diff
0
| Investor | Q1 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|